Javascript must be enabled to continue!
Management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients undergoing open-heart surgery
View through CrossRef
Background: There are scarce studies on the management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients during cardiac surgery. The purposes of this retrospective study were to present and evaluate our experience with G6PD deficient patients who underwent cardiac surgery with cardiopulmonary bypass (CPB).
Methods: We included 20 patients with G6PD deficiency who had cardiac surgeries from 2015 to 2019. We used free radical scavenging strategy and careful perioperative management. The patients were compared to a control group of 20 patients with normal G6PD enzyme activity who underwent the same type of operations in the same period.
Results: Males represented 80% of G6PD deficient patients. There were significant elevations in preoperative total bilirubin (1.03±0.33 vs. 0.57±0.11 mg/dl, p< 0.001) and reticulocytes (1.87±0.62 vs. 0.54±0.18%) in G6PD deficient patients. Valve surgery was done for 60% of G6PD deficient patients. There were no significant differences between both groups regarding the type of surgery, aortic cross-clamp, CPB, and total operative time. G6PD deficient patients had significantly lower postoperative hemoglobin levels (9.44±0.94 vs. 10.0±0.59 g/dl, p= 0.04) and significantly higher postoperative total bilirubin (1.51±0.51 vs. 0.98±0.45 mg/dl; p=0.002) and reticulocytes (1.85±0.51 vs. 0.57±0.13%; p< 0.001). There was no significant difference regarding postoperative urea and creatinine levels. Ventilation time (10.3±2.7 vs. 8.2±1.9 hours; p=0.01), ICU stay (3.1±0.87 vs. 2.3±0.71 days; p=0.004), and hospital stay (3.1±0.87 vs. 6.0±1.02 days; p<0.001) significantly increased in G6PD deficient patients. The mortality rate was 5% (one patient) in G6PD deficient patients.
Conclusion: Despite the management strategy, G6PD deficient patients undergoing cardiac surgery are more liable to hemolysis and hypoxia with more need for blood transfusion and longer ventilation time, ICU, and hospital stays when compared to patients with normal G6PD enzyme activity. Further research to improve the outcomes in G6PD deficient patients is required.
The Egyptian Society of Cardiothoracic Surgery
Title: Management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients undergoing open-heart surgery
Description:
Background: There are scarce studies on the management of glucose 6-phosphate dehydrogenase (G6PD) deficient patients during cardiac surgery.
The purposes of this retrospective study were to present and evaluate our experience with G6PD deficient patients who underwent cardiac surgery with cardiopulmonary bypass (CPB).
Methods: We included 20 patients with G6PD deficiency who had cardiac surgeries from 2015 to 2019.
We used free radical scavenging strategy and careful perioperative management.
The patients were compared to a control group of 20 patients with normal G6PD enzyme activity who underwent the same type of operations in the same period.
Results: Males represented 80% of G6PD deficient patients.
There were significant elevations in preoperative total bilirubin (1.
03±0.
33 vs.
0.
57±0.
11 mg/dl, p< 0.
001) and reticulocytes (1.
87±0.
62 vs.
0.
54±0.
18%) in G6PD deficient patients.
Valve surgery was done for 60% of G6PD deficient patients.
There were no significant differences between both groups regarding the type of surgery, aortic cross-clamp, CPB, and total operative time.
G6PD deficient patients had significantly lower postoperative hemoglobin levels (9.
44±0.
94 vs.
10.
0±0.
59 g/dl, p= 0.
04) and significantly higher postoperative total bilirubin (1.
51±0.
51 vs.
0.
98±0.
45 mg/dl; p=0.
002) and reticulocytes (1.
85±0.
51 vs.
0.
57±0.
13%; p< 0.
001).
There was no significant difference regarding postoperative urea and creatinine levels.
Ventilation time (10.
3±2.
7 vs.
8.
2±1.
9 hours; p=0.
01), ICU stay (3.
1±0.
87 vs.
2.
3±0.
71 days; p=0.
004), and hospital stay (3.
1±0.
87 vs.
6.
0±1.
02 days; p<0.
001) significantly increased in G6PD deficient patients.
The mortality rate was 5% (one patient) in G6PD deficient patients.
Conclusion: Despite the management strategy, G6PD deficient patients undergoing cardiac surgery are more liable to hemolysis and hypoxia with more need for blood transfusion and longer ventilation time, ICU, and hospital stays when compared to patients with normal G6PD enzyme activity.
Further research to improve the outcomes in G6PD deficient patients is required.
Related Results
Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand
Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand
AbstractBackgroundG6PD deficiency is common in malaria endemic regions and is estimated to affect more than 400 million people worldwide. Treatment of malaria patients with the ant...
PREVALENCE AND MOLECULAR CHARACTERIZATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY IN FEMALES FROM PREVIOUSLY MALARIA ENDEMIC REGIONS IN NORTHEASTERN THAILAND AND IDENTIFICATION OF A NOVEL G6PD VARIANT
PREVALENCE AND MOLECULAR CHARACTERIZATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY IN FEMALES FROM PREVIOUSLY MALARIA ENDEMIC REGIONS IN NORTHEASTERN THAILAND AND IDENTIFICATION OF A NOVEL G6PD VARIANT
Introduction: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common X-linked enzymopathy, highly prevalent in areas where malaria is or has been endemic. Prevalenc...
Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy
Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy
Abstract
Background: Numerous studies have shown that glucose-6-phosphate dehydrogenase (G6PD) is a tumor-promoting factor in a variety of malignancies. However, it is not ...
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in
Plasmodium vivax
malaria. This open-label, dose-esca...
Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Abstract
Cancer cells are characterized by an excess of reactive oxygen species (ROS) levels, which are balanced by high levels of glutathione (GSH) to protect again...
A comparative study between glucose 6-phosphate dehydrogenase deficient and normal term neonates with indirect hyperbilirubinemia in a rural tertiary care hospital of Eastern India
A comparative study between glucose 6-phosphate dehydrogenase deficient and normal term neonates with indirect hyperbilirubinemia in a rural tertiary care hospital of Eastern India
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an important cause of neonatal indirect hyperbilirubinemia or even kernicterus leading to long-term neurological ...
Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy
Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy
Background
Enhanced glucose metabolism has been reported in many cancers. Glucose-6-phosphate dehydrogenase (G6PD) is a rate-limiting enzyme involved in the pento...
G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression
G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is a cell metabolic disease with high metastasis rate and poor prognosis. Our previous studies demonstrate that...

